- Home
- CHW vs CATX Comparison
CHW vs CATX Comparison
Compare CHW & CATX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | CHW | CATX |
|---|---|---|
| Founded | N/A | 1983 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | Medical/Dental Instruments |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 523.0M | 569.6M |
| IPO Year | 2007 | 2018 |
Fundamental Metrics
Financial Performance| Metric | CHW | CATX |
|---|---|---|
| Price | $7.47 | $4.35 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 9 |
| Target Price | N/A | ★ $12.11 |
| AVG Volume (30 Days) | 202.6K | ★ 1.3M |
| Earning Date | 01-01-0001 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $12.71 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $5.55 | $1.60 |
| 52 Week High | $8.34 | $6.16 |
Technical Indicators
Market Signals| Indicator | CHW | CATX |
|---|---|---|
| Relative Strength Index (RSI) | 48.22 | 45.41 |
| Support Level | $7.44 | $3.24 |
| Resistance Level | $7.77 | $4.64 |
| Average True Range (ATR) | 0.19 | 0.33 |
| MACD | 0.04 | -0.03 |
| Stochastic Oscillator | 82.20 | 42.39 |
Price Performance
Historical ComparisonAbout CHW Calamos Global Dynamic Income Fund
Calamos Global Dynamic Income Fund operates as a closed-end management investment company. The company's investment objective is to generate a high level of current income with the objective of capital appreciation. It dynamically allocates its investment among equities, convertible bonds, fixed-income securities, and alternative investments.
About CATX Perspective Therapeutics Inc.
Perspective Therapeutics Inc is a radiopharmaceutical development company that is pioneering advanced treatment applications for cancers throughout the body. The Company has a proprietary technology that utilizes the alpha-emitting isotope Lead-212 (212Pb) to deliver powerful radiation specifically to cancer cells via specialized targeting moieties.